Quantum Genesis AI Corp. (OTC: QGAI) has achieved a significant milestone by securing the removal of the Caveat Emptor designation previously applied to its securities by OTC Markets Group, the company announced on June 1, 2026. This designation, often applied to companies with concerns about public interest or disclosure, had raised red flags for investors. Its removal indicates that Quantum Genesis AI has addressed those concerns and met OTC Markets’ requirements for transparency and information sharing.
The company worked cooperatively with OTC Markets throughout the review process, providing information and responding to inquiries. CEO Naveen Kulkarni expressed appreciation for OTC Markets’ professionalism and assistance, stating, “We are pleased that the review process has concluded with the removal of the Caveat Emptor designation.” He emphasized the company’s focus on transparency, responsiveness, and constructive engagement during the period.
This development is crucial for Quantum Genesis AI as it seeks to restore investor confidence and access to capital markets. The Caveat Emptor label often deters potential investors and limits trading liquidity. With its removal, the company can now attract a broader investor base and pursue its strategic initiatives in artificial intelligence, computational modeling, and scientific innovation without the stigma of the designation.
Quantum Genesis AI continues to advance its technologies at the intersection of AI and computational modeling, aiming to support research and development across emerging sectors. The company remains committed to responsible corporate governance and public company compliance, pledging to provide timely updates on its business activities and corporate developments through public disclosures and shareholder communications.
For more information, visit www.qgaicorp.com and the company’s profile at www.otcmarkets.com/stock/QGAI.
